WO2024042466 - BRAIN PENETRATING PEPTIDES AND METHODS OF USE THEREOF
National phase entry:
Publication Number
WO/2024/042466
Publication Date
29.02.2024
International Application No.
PCT/IB2023/058366
International Filing Date
23.08.2023
Title **
[English]
BRAIN PENETRATING PEPTIDES AND METHODS OF USE THEREOF
[French]
PEPTIDES PÉNÉTRANT DANS LE CERVEAU ET LEURS PROCÉDÉS D'UTILISATION
Applicants **
UNIVERSITY OF TARTU
Inventors
PÕŠNOGRAJEVA, Kristina
TOOME, Kadri
HAUGAS, Maarja
TEESALU, Tambet
Priority Data
63/373,160
22.08.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 4038 | |
| EPO | Filing, Examination, Granting | 35822 | |
| Japan | Filing, Examination, Granting | 3400 | |
| South Korea | Filing, Examination, Granting | 4537 | |
| USA | Filing, Examination, Granting | 18790 |
Total:
66,587
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Polypeptides that traverse the blood-brain-barrier (BBB) are disclosed. The peptide can serve as BBB-traversing transport vehicles for delivering active agents from the circulation into across the BBB to contact cells and tissues within the CNS and/or brain. Therefore, composition of conjugates including polypeptides that traverse the BBB, conjugated with one or more active agents are provided. The BBB-traversing peptides can be a fusion protein that includes one or more additional domains such as a targeting moiety, a linker, an active agent, a purification tag, or any combination thereof. Exemplary BBB- traversing peptides include polypeptides having an amino acid sequence RRVISRAKLAAAL (SEQ ID NO:1), or a functional variant thereof, or the amino acid sequence of CVGTNCY (SEQ ID NO:2).[French]
L'invention concerne des polypeptides qui traversent la barrière hémato-encéphalique (BHE). Le peptide peut servir de véhicules de transport traversant la BHE pour administrer des agents actifs à partir de la circulation à travers la BHE pour entrer en contact avec des cellules et des tissus à l'intérieur du SNC et/ou du cerveau. Par conséquent, l'invention concerne une composition de conjugués comprenant des polypeptides qui traversent la BHE, conjugués à un ou plusieurs agents actifs. Les peptides traversant la BHE peuvent être une protéine de fusion qui comprend un ou plusieurs domaines supplémentaires tels qu'une fraction de ciblage, un lieur, un agent actif, une étiquette de purification, ou toute combinaison de ceux-ci. Des exemples de peptides traversant la BHE comprennent des polypeptides ayant une séquence d'acides aminés RRVISRAKLAAAL (SEQ ID NO:1), ou un variant fonctionnel de celle-ci, ou la séquence d'acides aminés de CVGTNCY (SEQ ID NO:2).